AllianceBernstein’s Crescent Biopharma CBIO Stock Holding History

AllianceBernstein’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-728	Closed	-$219K	–	3357
2021 Q1	$219K	Hold	728	–	–	﹤0.01%	3026
2020 Q4	$274K	Hold	728	–	–	﹤0.01%	2899
2020 Q3	$223K	Sell	728 -26	-3%	-$9.94K	﹤0.01%	2933
2020 Q2	$284K	Buy	754 +276	+58%	+$78.1K	﹤0.01%	2901
2020 Q1	$109K	Buy	478 +42	+10%	+$16.1K	﹤0.01%	2942
2019 Q4	$231K	Hold	436	–	–	﹤0.01%	2874
2019 Q3	$188K	Buy	436 +71	+19%	+$45.7K	﹤0.01%	2962
2019 Q2	$435K	Buy	365 +42	+13%	+$50.2K	﹤0.01%	2665
2019 Q1	$402K	Buy	323 +40	+14%	+$45.8K	﹤0.01%	2623
2018 Q4	$268K	Buy	283 +58	+26%	+$69.8K	﹤0.01%	2778
2018 Q3	$324K	Buy	225 +69	+44%	+$104K	﹤0.01%	2810
2018 Q2	$252K	Buy	+156	New	+$268K	﹤0.01%	2876
2014 Q2	–	Sell	-2	Closed	-$3K	–	3497
2014 Q1	$3K	Buy	+2	New	+$2.42K	﹤0.01%	3369

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein's CBIO Position: Q2 2021 in Review

AllianceBernstein sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 728 shares — an estimated $219K sold.

AllianceBernstein first reported a position in CBIO in Q1 2014 and held it in 13 quarters. The position peaked at $435K in Q2 2019. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

AllianceBernstein reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 728 Crescent Biopharma shares in Q2 2021, an estimated $219K.
AllianceBernstein first reported a position in Crescent Biopharma in Q1 2014 and held it in 13 quarters.
AllianceBernstein's Crescent Biopharma position peaked at $435K in Q2 2019.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.